Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists

Abstract

Purpose of review:Use of gadolinium-based contrast agents (GBCA) in renal impairment is controversial, with physician and patient apprehension in acute kidney injury (AKI), chronic kidney disease (CKD), and dialysis because of concerns regarding nephrogenic systemic fibrosis (NSF). The position that GBCA are absolutely contraindicated in AKI, category G4 and G5 CKD (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2), and dialysis-dependent patients is outdated and may limit access to clinically necessary contrast-enhanced magnetic resonance imaging (MRI) examinations. This review and clinical practice guideline addresses the discrepancy between existing Canadian guidelines regarding use of GBCA in renal impairment and NSF.Sources of information:Published literature (including clinical trials, retrospective cohort series, review articles, and case reports), online registries, and direct manufacturer databases were searched for reported cases of NSF by class and specific GBCA and exposed patient population.Methods:A comprehensive review was conducted identifying cases of NSF and their association to class of GBCA, specific GBCA used, patient, and dose (when this information was available). Based on the available literature, consensus guidelines were developed by an expert panel of radiologists and nephrologists.Key findings:In patients with category G2 or G3 CKD (eGFR ≥ 30 and < 60 mL/min/1.73 m2), administration of standard doses of GBCA is safe and no additional precautions are necessary. In patients with AKI, with category G4 or G5 CKD (eGFR < 30 mL/min/1.73 m2) or on dialysis, administration of GBCA should be considered individually and alternative imaging modalities utilized whenever possible. If GBCA are necessary, newer GBCA may be administered with patient consent obtained by a physician (or their delegate) citing an exceedingly low risk (much less than 1%) of developing NSF. Standard GBCA dosing should be used; half or quarter dosing is not recommended and repeat injections should be avoided. Dialysis-dependent patients should receive dialysis; however, initiating dialysis or switching from peritoneal to hemodialysis to reduce the risk of NSF is unproven. Use of a macrocyclic ionic instead of macrocyclic nonionic GBCA or macrocyclic instead of newer linear GBCA to further prevent NSF is unproven. Gadopentetate dimeglumine, gadodiamide, and gadoversetamide remain absolutely contraindicated in patients with AKI, those with category G4 or G5 CKD, or those on dialysis. The panel agreed that screening for renal disease is important but less critical when using macrocyclic and newer linear GBCA. Monitoring for and reporting of potential cases of NSF in patients with AKI or CKD who have received GBCA is recommended.Limitations:Limited available literature (number of injections and use in renal impairment) regarding the use of gadoxetate disodium. Limited, but growing and generally high-quality, number of clinical trials evaluating GBCA administration in renal impairment. Limited data regarding the t...

Non-contrast MRI protocol for TAVI guidance: quiescent-interval single-shot angiography in comparison with contrast-enhanced CT

“…1 Bland-Altman plot for differences in minimum access vessel diameter between QISS-MRA and CTA. The red line on the Bland-Altman graph represents the mean, the upper green line represents + 2 standard deviations (SD), and the lower green line represents − 2 SD [6]. However, the rapidly growing interest in more sophisticated, non-contrast MR imaging is also driven by reports of intraand extracranial gadolinium depositions with currently unclear clinical significance [14].…”

“…Our study group recently presented a contrast-enhanced MRI protocol to provide measurements of aortic annulus and access routes with good to excellent agreement in comparison with CTA resulting in accordant decisions for prosthesis size as well as transfemoral TAVI access capability [5]. However, in patients with stage 4 and 5 renal impairment (estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m 2 ), rare cases of nephrogenic systemic fibrosis (NSF), a severe and potentially fatal condition without known effective treatment, were reported [6]. Moreover, recent reports of intracranial gadolinium deposition with currently unclear clinical relevance have fostered efforts to develop unenhanced MRI protocols [7,8].…”

Wie gefährlich ist die Kontrastmittelexposition für die Nieren? Strategien der Nephroprotektion

“…Dialysepatienten sollten danach eine Dialysebehandlung erhalten. Patienten müssen über das geringe (< 1 %) Risiko der Entwicklung einer NSF aufgeklärt werden [43].…”

Discrimination between Glioblastoma and Solitary Brain Metastasis: Comparison of Inflow-Based Vascular-Space-Occupancy and Dynamic Susceptibility Contrast MR Imaging

“…15,18 Besides, the administration of exogenous contrast agents required for DSC raises concerns about the adverse effects of gadolinium, especially the deposits in brain, even using macrocyclic gadolinium-based contrast agents. [19][20][21][22] Inflow-based vascular-space-occupancy (iVASO) is a completely noninvasive perfusion method that does not involve administration of an exogenous contrast agent. 23 Instead, proton spins in the water molecules in blood are exploited as an endogenous contrast agent by applying spatially selective radiofrequency inversion pulses.…”